NEW YORK (360Dx) – Following on a series of distribution agreements for markets around the world, Israeli molecular diagnostics firm MicroMedic is aiming to expand into the US with its liquid biopsy assay for detecting early-stage urothelial carcinoma.
According to MicroMedic, its CellDetect assay diagnoses bladder cancer in about twenty minutes using a unique plant-based dye that distinguishes between malignant and benign cells.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
